Category : Genetics
Blood disorders continue to pose a significant global health challenge, particularly in regions where inherited conditions are common. Among these, β-thalassemia stands out as one of the most serious and lifelong genetic diseases affecting millions worldwide. In India, the burden is especially high, making it not just a medical issue but a public health priority
Understanding Beta-Thalassemia
β-thalassemia is a hereditary disorder resulting from pathogenic mutations in the HBB gene, which encodes the beta-globin subunit essential for hemoglobin synthesis. Hemoglobin an iron-containing metalloprotein, is responsible for oxygen transport in erythrocytes, which maintains functionality through a stoichiometric balance between the alpha- and beta-globin chains. This imbalance forms the basis of the disease mechanism. When beta-globin production is reduced or absent, the following changes occur:
- Excess alpha chains accumulate within erythroid precursors, forming insoluble aggregates that generate reactive oxygen species and trigger membrane damage.
- Red blood cell precursors are damaged when they undergo premature destruction in the bone marrow.
- Ineffective erythropoiesis is characterised by a high rate of intramedullary red cell death despite compensatory expansion of erythroid activity.
- Chronic hemolytic anemia develops due to a reduced number of circulating red blood cells.
β-thalassemia follows an autosomal recessive pattern of inheritance, which means the disease only fully develops when a person inherits defective copies of the HBB gene from both parents as one mutation alone simply isn’t enough to trigger the condition and those who carry only one mutated copy are clinically referred to as thalassemia minor and typically go through life without any noticeable symptoms- asymptomatic and yet can unknowingly pass the faulty gene down to their children.
Clinical Burden: A Lifelong Struggle
The clinical presentation of β-thalassemia is shaped largely by the severity of the disease, though in most cases, the symptoms trace back to two central problems- chronic anemia and the body’s persistent failure to produce functional red blood cells.
The immediate symptoms of the patients include:
- Fatigue, pallor, and weakness which arise from the blood’s reduced ability to carry and deliver oxygen to the tissues.
- Failure to thrive and feeding difficulties
- Progressive enlargement of both spleen and liver(hepatosplenomegaly)
- Skeletal changes due to marrow expansion and growth retardation
- Recurrent infections reflecting compromised and overburdened immune response
Patients with severe forms, particularly thalassemia major, fall under transfusion-dependent thalassemia (TDT) and require life-long blood transfusion to survive, and yet these very transfusions drive a relentless accumulation of excess iron in the body. Iron overload stands as one of the most serious and life-altering complications of the disease, which progressively damages vital organs, including the heart, liver and endocrine system. Critically, this burden is not confined to TDT alone; patients with non-transfusion dependent thalassemia (NTDT) face the same threat through a different route, such as ineffective erythropoiesis which suppresses hepcidin, the body’s iron-regulating hormone, triggering excessive intestinal iron absorption that silently accumulates over time.
India’s Burden: A Silent Epidemic
India bears one of the heaviest burdens of β-thalassemia in the world- a reality that continues to grow in scale yet remains underrecognized in public events. The numbers are staggering an estimated 30-40 million people carry the trait, and between 10,000-15,000 children are born with thalassemia major every year. In certain communities, the carrier frequencies climb as high as 10-15%, meaning one in ten people within this population may be heterozygous carriers and unknowingly transmit the mutant HBB allele to future generations.
Despite the scale of the disease, timely diagnosis remains a significant challenge across much of the country. Detecting β-thalassemia trait is complicated by the widespread co-existence of nutritional deficiencies, particularly iron deficiency anemia, which can mask characteristic hematological markers and complicate screening outcomes.
Key challenges shaping the gaps in India incude:
- Limited access to advanced diagnostics in routine screening in rural areas
- High cost and logistical burden of lifelong treatment, lifelong dependency on transfusion therapy, which places a sustained pressure on both families and the healthcare infrastructure.
- Absence of mandatory antenatal screening programs, though the initiative is optional, is nevertheless much required.
- And for the most part, limited access to genetic counselling, which remains critical to address stigmatization and help at-risk families understand the implications of carrier status
Current Treatment: Managing, Not Curing
Howβ-thalassemia is managed depends almost entirely on how severe the disease is. The carriers those with thalassemia trait typically do not need treatment, but the genetic counselling is strongly recommended, particularly for couples who are planning to have children. Management strategies primarily focus on symptom control:
- Blood Transfusions
For patients with β-thalassemia major, blood transfusion is a lifelong necessity. Without them, the body simply cannot maintain hemoglobin levels adequate to sustain normal function. - Iron Chelation
As iron overload eventually becomes a significant clinical concern, the anemia itself requires chelation therapy, thus runs alongside transfusions almost from the start. Deferoxamine, Deferiprone, and Deferasirox each work through different routes and schedules, and the choice between them depends on the patient’s iron burden, age, tolerance and access. - Bone Marrow transplantation
Bone marrow transplantation remains the only treatment that can actually cure beta-thalassemia, though the practice remains inaccessible and is constrained by the difficulty of finding a compatible donor, and the cost alone puts transplantation firmly out of reach for most families. - Gene Therapy
This is part of what makes the field’s growing interest in gene therapy so significant. Gene therapy addressed the very limitations that have kept BMT from being a realistic option for the majority of those who need it.
Gene Therapy: A Transformative Breakthrough
This is where the future becomes far more promising.
Gene therapy a technique that aims to address the root cause of β-thalassemia and not just try to ease or eliminate the symptoms.
Gene therapy works by targeting the defective HBB gene itself, aiming to restore what beta thalassemia takes away at the fundamental level that is, the body’s ability to produce functional beta-globin on its own.
It working principle is that the patient’s own hematopoietic stem cells are harvested from the bone marrow or peripheral blood, and a working copy of the beta-globin gene is delivered into these cells through a viral vector. Then the genetically corrected cells are infused back into the patient. Once grafted, they begin producing healthy functional hemoglobin.
The landmark development in this field is betibeglogene automecl, the first FDA-approved gene therapy for transfusion-dependent beta thalassemia, which demonstrated transfusion independence in the majority of treated patients across clinical trials.
The treatment offers what the conventional treatment cannot, such as:
- A single intervention with the potential to be curative rather than ongoing.
- Sustained reduction or complete elimination of transfusion dependency.
- Significantly lower risk of iron accumulation, therefore, reduced organ damage over time.
- And finally, a measurable improvement in overall quality of life across physical and psychological domains.
Challenges for Gene Therapy in India
Despite its promise, gene therapy faces several barriers in India:
- Extremely high in cost and remains prohibitive for the vast majority of Indian families.
- The infrastructure for the advanced cell-based therapies is still limited across most of the country
- Long-term safety and durability data is still being gathered from ongoing trails
- Regulatory frameworks and reimbursement pathways for gene therapies are yet to be fully established.
However, with growing investment in biotechnology and initiatives like “ Make in India” in healthcare, there is hope that gene therapy may become more accessible in the near future.
The Way Forward
Addressing β-thalassemia in India at scale requires movement on several fronts simultaneously. Such as Awareness remains foundational across urban and rural populations alike, education around carrier status, screening and genetic risk. A nationwide control programme will need more than intent, requiring trained genetic counsellors, quality-controlled screening centres, and at least one government-run prenatal diagnosis facility per state. And for patients already living with the disease, particularly as this population ages, their needs grow more complex. Stem cell transplantation should be actively encouraged for low-risk patients, and expanding transplant programmes within government hospitals would go a long way toward making the option financially viable for more families.
Conclusion
β-thalassemia represents a significant yet preventable health burden in India. While current treatments have improved survival, they do not offer a definitive cure for most patients. Gene therapy, however, is changing the landscape—offering the possibility of a life free from transfusions and complications.
The challenge now lies in bridging the gap between innovation and accessibility, ensuring that breakthroughs in science translate into real-world impact for millions affected by this disorder.
Written by,
Dr. Jyothi M N
Senior Project associate-DST-PURSE
Department of Medical Genetics
JSS Medical College and Hospital
JSS Academy of Higher Education and Research, Mysuru